Citations

Clear

89 citation(s) found for "Lightner, A L".

Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease
Yung, Diana E., Horesh, Nir , Ben‐Horin, Shomron , Eliakim, Rami, Koulaouzidis, Anastasios , Lightner, Amy L. , Kopylov, Uri

Mayo Clinic

Inflammatory Bowel Diseases | May 17, 2018 | Volume: 24 | Issue: 11 | Pages: 2327-2338

10.1093/ibd/izy156 | PMID 29788385 Get It

The Impact of Age at Time of Ileal Pouch Anal Anastomosis on Short and Long-Term Outcomes in Adults
McKenna, Nicholas P. , Mathis, Kellie L. , Pembérton, John H., Lightner, Amy L. , McKenna, Nicholas P

Mayo Clinic

Inflammatory Bowel Diseases | April 26, 2018 | Volume: 24 | Issue: 8 | Pages: 1857-1865

10.1093/ibd/izy087 | PMID 29718243 Get It

A Systematic Review and Meta-analysis of Mesenchymal Stem Cell Injections for the Treatment of Perianal Crohn’s Disease: Progress Made and Future Directions
Dozois, Eric J. , Lightner, Amy L. , Wang, Zhen , Zubair, Abba C.

Mayo Clinic

Diseases of the Colon & Rectum | March 25, 2018 | Volume: 61 | Issue: 5 | Pages: 629-640

10.1097/dcr.0000000000001093 | PMID 29578916 Get It

BACKGROUND: There has been a surge in clinical trials studying the safety and efficacy of mesenchymal stem cells for the treatment of perianal Crohn’s disease. OBJECTIVE: The purpose of this work was to systematically review the literature to determine safety and efficacy of mesenchymal stem cells for the treatment of refractory perianal Crohn’s disease. DATA SOURCES: Sources included PubMed, Cochrane Library Central Register of Controlled Trials, and Embase. STUDY SELECTION: Studies that reported safety and/or efficacy of mesenchymal stem cells for the treatment of perianal Crohn’s disease were included. Two independent assessors reviewed eligible articles. INTERVENTION: The study intervention was delivery of mesenchymal stem cells to treat perianal Crohn’s disease. MAIN OUTCOMES MEASURES: Safety and efficacy of mesenchymal stem cells used to treat perianal Crohn’s disease were measured. RESULTS: Eleven studies met the inclusion criteria and were included in the systematic review. Three trials with a comparison arm were included in the meta-analysis. There were no significant increases in adverse events (OR = 1.07 (95% CI, 0.61–1.89); p = 0.81) or serious adverse events (OR = 0.53 (95% CI, 0.28–0.98); p = 0.04) in patients treated with mesenchymal stem cells. Mesenchymal stem cells were associated with improved healing as compared with control subjects at primary end points of 6 to 24 weeks (OR = 3.06 (95% CI, 1.05–8.90); p = 0.04) and 24 to 52 weeks (OR = 2.37 (95% CI, 0.90–6.25); p = 0.08). LIMITATIONS: The study was limited by its multiple centers and heterogeneity in the study inclusion criteria, mesenchymal stem cell origin, dose and frequency of delivery, use of scaffolding, and definition and time point of fistula healing. CONCLUSIONS: Although there have been only 3 trials conducted with control arms, existing data demonstrate improved efficacy and no increase in adverse or serious adverse events with mesenchymal stem cells as compared with control subjects for the treatment of perianal Crohn’s disease.
Perioperative Management of Biologic and Immunosuppressive Medications in Patients With Crohn’s Disease
Lightner, Amy L., Lightner, Amy L.

Mayo Clinic

Diseases of the Colon & Rectum | March 8, 2018 | Volume: 61 | Issue: 4 | Pages: 428-431

10.1097/dcr.0000000000001072 | PMID 29521822 Get It

Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis
Mouchli, Mohamad, Singh, Siddharth , Boardman, Lisa, Bruining, David H. , Rosen, Charles B. , Poterucha, John J., Watt, Kymberly D. , Kane, Sunanda V. , Raffals, Laura E. , Loftus, Edward V. , Mouchli, Mohamad A, Hasan, Bashar , Loftus, Edward V , Boardman, Lisa, Lightner, Amy L. , Heimbach, Julie K. , Hasan, Bashar

Mayo Clinic

Inflammatory Bowel Diseases | March 7, 2018 | Volume: 24 | Issue: 5 | Pages: 1074-1081

10.1093/ibd/izx096 | PMID 29522202 Get It

Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study
Mathis, Kellie L. , Tse, Chung Sang , Pembérton, John H., Shen, Bo , Kochhar, Gursimran , Singh, Amandeep , Dulai, Parambir S. , Eisenstein, Samuel , Sandborn, William J. , Parry, Lisa, Stringfield, Sarah , Hudesman, David , Remzi, Feza H. , Loftus, Edward V. , Tse, C S , Loftus, Edward V , Lightner, Amy L.

Mayo Clinic

Inflammatory Bowel Diseases | March 2, 2018 | Volume: 24 | Issue: 4 | Pages: 871-876

10.1093/ibd/izx076 | PMID 29509927 Get It

Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease
Law, Cindy C Y , Narula, Alisha, McKenna, Nicholas P. , Narula, Neeraj , Lightner, Amy L. , Colombel, Jean‐Frédéric , McKenna, Nicholas P

Mayo Clinic

Journal of Crohn's and Colitis | February 22, 2018 | Volume: 12 | Issue: 5 | Pages: 538-545

10.1093/ecco-jcc/jjy022 | PMID 29718245 Get It

Segmental Resection versus Total Proctocolectomy for Crohn’s Colitis: What is the Best Operation in the Setting of Medically Refractory Disease or Dysplasia?
Lightner, Amy L.

Mayo Clinic

Inflammatory Bowel Diseases | February 16, 2018 | Volume: 24 | Issue: 3 | Pages: 532-538

10.1093/ibd/izx064 | PMID 29462390 Get It

Duodenal Crohn’s Disease
Lightner, Amy L.

Mayo Clinic

Inflammatory Bowel Diseases | February 16, 2018 | Volume: 24 | Issue: 3 | Pages: 546-551

10.1093/ibd/izx083 | PMID 29462397 Get It

Editorial Commentary
Lightner, Deborah J., Lightner, Deborah

Mayo Clinic

Urology Practice | February 13, 2018 | Volume: 5 | Issue: 3 | Pages: 232-232

10.1016/j.urpr.2017.03.029 | PMID 37300221 Get It